| Name, year |
Type of study |
n, Study /Control |
Anticoagulation protocol |
Follow-up period |
Thromboembolic complications, n (%) |
Bleeding events, n(%) |
|
|
|
|
|
AG |
VG |
p |
AG |
VG |
p |
| Di Biase et al, 2015 |
Prospective multicenter registry |
400; 200/200 |
Apixaban 2.5 mg or 5 mg two times a day according to creatinine clearance for up to 3 weeks pre-procedurally. Patients were instructed to take their apixaban dose the morning of the procedure without any discontinuation and to take next dose the same night of the procedure. |
30 days post-procedure |
0 |
0 |
>0.99 |
9 (4.5%) |
6 (3%) |
0.43 |
| Nagao et al, 2014 |
Retrospective case control study |
342; 105/237 |
Anticoagulation was started 4 weeks before; apixaban was dosed into 2.5 mg or 5 mg two times a day based on creatinine clearance, age (2.5 mg BID for ≥ 80 yrs) and weight (2.5 mg for ≤ 60 kg). On the procedural day, the dose of apixaban was administered in the morning and in the night as usual days in the Apixaban group. |
3 months post-procedure |
0 |
1 (0.4%) |
0.51 |
5(5%) |
15 (6%) |
0.57 |
| Kaess et al, 2014 |
Prospective case control study |
325; 105/210 |
Anticoagulation atleast 4 weeks before the procedure; All patients received apixaban 2.5 mg in the morning of procedure followed by their usual dosage in the evening; 95% of patients in apixaban were on 5 mg BID and 5% on 2.5 BID |
Till the time of discharge (2 days for majority of patients) |
0 |
0 |
>0.99 |
11 (10.5%) |
26 (12.3%) |
0.71 |
